Five Ebola research projects, including a large-scale clinical trial of a potential vaccine, will receive EUR 24.4 million funding as the European Commission activates an emergency fast-track procedure that enables it to release research cash in urgent situations, such as an epidemic.
José Manuel Barroso, President of the European Commission, said: ‘We're in a race against time on Ebola, and we must address both the emergency situation and at the same time have a long-term response.’
In addition to the Ebola vaccine trial, which will receive EUR 15 million, funding has been allocated to a study into how the Ebola virus interacts with its host, as well as research into potential treatments stemming from an influenza antiviral drug, antibodies from horses, and blood and serum from survivors.
The projects were selected following proposals from research teams inside and outside the EU, and were evaluated by an independent group of experts.
‘We need to step up medical research on Ebola,’ said EU Research, Innovation and Science Commissioner Máire Geoghegan-Quinn. ‘These projects enlist the best academic researchers and industry to take the fight to this deadly disease.’
The Commission has asked the European and Developing Countries Clinical Trials Partnership (EDCTP) – which was set up in 2003 to accelerate the development of vaccines and treatments for HIV/AIDS, tuberculosis and malaria – to widen its remit to include emerging epidemics of concern to Africa, such as Ebola.
‘We're in a race against time on Ebola, and we must address both the emergency situation and at the same time have a long term response.’
José Manuel Barroso, President of the European Commission
This will allow the EDCTP to fund clinical trials on drugs, vaccines and diagnostics for Ebola.
The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative, a public-private partnership that aims to speed up the development of better and safer medicines for patients.
The announcement comes as the World Health Organization (WHO) hosts a high-level meeting in Geneva, Switzerland, where representatives from the international community and industry will discuss access to near-term vaccines, the financing of vaccine and immunisation campaigns and the design, production capacity, regulation and indemnity of clinical trials.
The current Ebola outbreak in West Africa has claimed the lives of nearly 5 000 people since the first cases were discovered in March this year. It is the largest and most complex outbreak of the disease since the virus was first discovered in 1976.
The European Union has been active from the early stages, with the European Commission alone having already pledged EUR 180 million of humanitarian and development aid to help the countries affected by the epidemic. This includes the provision of immediate healthcare to affected communities and help in containing the spread of the epidemic through rapid diagnosis and disease awareness campaigns.
The EU is also contributing to fight the epidemic with experts' presence on the ground and coordination for the delivery of supplies and possible evacuations.
Under its previous funding programme, the Commission is already funding Ebola research into the development of new antiviral drugs, how to link up high-security laboratories, the clinical management of patients, particularly in Europe, and solutions to ethical, administrative, regulatory and logistical bottlenecks that prevent a rapid research response.
Tiny pieces of plastic, now ubiquitous in the marine environment, have long been a cause of concern for their ability to absorb toxic substances and potentially penetrate the food chain. Now scientists are beginning to understand the level of threat posed to life, by gauging the extent of marine accumulation and tracking the movement of these contaminants.
Testing the safety of medicines and chemicals on organ-like structures developed from various types of stem cells could reduce the reliance on animal testing and streamline chemical and drug development, according to scientists in the Netherlands who are in the early stages of developing such technology.
The world’s largest radio telescope, known as the Square Kilometre Array (SKA) and situated over two continents, will be able to detect the first stars and galaxies emerging from the ‘murk’ at the beginning of the universe and much more besides, according to Professor Phil Diamond, Director General of SKA. He spoke to Horizon at the opening of the Shared Sky art exhibition in Brussels, Belgium on 16 April, where indigenous artists from SKA host nations South Africa and Australia use traditional painting and folk art to explore the themes of astronomy, spirituality and a borderless sky.
Electric ferries and digital communication between ships could help in the quest to decarbonise maritime transport, a sector which is often perceived as being the green option but could still do much to lower its environmental footprint.
Tiny plastic particles could impact human health.
Astronomers could use giant radio telescope from 2025.
The EU’s research chief on his new role.